Clinical efficacy and safety of paclitaxel or docetaxel combined with oxaliplatin or cisplatin and fluorouracil or tiggio in the treatment of advanced gastric cancer / 中国基层医药

ABSTRACT

Objective To compare the treatment effect and adverse reaction of oxaliplatin and tiggio and paclitaxel or docetaxel combined with oxaliplatin or cisplatin and fluorouracil or tiggio in the treatment of advanced gastric cancer.Methods From January 2015 to April 2018, 60 patients with advanced gastric cancer were selected from Department of Oncology of the First Affiliated Hospital of Anhui Medical University.The patients were randomly divided into two groups according to the principle of simple randomization,with 30 cases in each group.The control group was treated with oxaliplatin + tiggio.The observation group was given paclitaxel (or docetaxel) combined with oxaliplatin (or cisplatin) and fluorouracil.The incidence of adverse reactions(hematotoxicity and non-hematologic toxicity),the efficacy(CR,PR,SD,PD) of the two groups were compared.Results The RR level of the observation group was 66.7% ,which was significantly higher than 40.0% of the control group (χ2 =4.286,P<0.05).There were no statistically significant differences between the two groups in incidence of adverse reactions such as thrombo-cytopenia,impaired liver function, anemia, oral mucositis, nausea and vomiting and neurotoxicity ( all P >0.05). Conclusion Treatment of advanced gastric cancer with FLOT or DCF can improve efficacy without increasing side effects.